Table of Contents Table of Contents 2 Introduction 5 Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Overview 7 Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Therapeutics Development 8 Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Therapeutics Assessment 26 Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Companies Involved in Therapeutics Development 33 Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Drug Profiles Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Dormant Products Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Discontinued Products Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Product Development Milestones Appendix

List of Tables Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Number of Products under Investigation by Universities/Institutes, H1 2019 Products under Investigation by Universities/Institutes, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 (Contd..1), H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Pipeline by Bayer AG, H1 2019 Pipeline by Deciphera Pharmaceuticals Inc, H1 2019 Pipeline by Eddingpharm Inc, H1 2019 Pipeline by Eisai Co Ltd, H1 2019 Pipeline by Eli Lilly and Co, H1 2019 Pipeline by Exelixis Inc, H1 2019 Pipeline by PharmAbcine Inc, H1 2019 Pipeline by Q BioMed Inc, H1 2019 Pipeline by Samjin Pharm Co Ltd, H1 2019 Dormant Products, H1 2019 Dormant Products, H1 2019 (Contd..1), H1 2019 Dormant Products, H1 2019 (Contd..2), H1 2019 Discontinued Products, H1 2019List of Figures Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Top 10 Indications, H1 2019 Number of Products by Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Routes of Administration, H1 2019 Number of Products by Stage and Routes of Administration, H1 2019 Number of Products by Molecule Types, H1 2019 Number of Products by Stage and Molecule Types, H1 2019

Bayer AG Deciphera Pharmaceuticals Inc Eddingpharm Inc Eisai Co Ltd Eli Lilly and Co Exelixis Inc PharmAbcine Inc Q BioMed Inc Samjin Pharm Co Ltd